GlaxoSmithKline (GSK) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
GlaxoSmithKline (GSK) quarterly earnings & revenue
GlaxoSmithKline (GSK) reported revenue of $10.25B for Q1 2026, up 1.5% year-over-year, with net income of $2.33B and diluted EPS of $1.16.
Over the last four reported quarters, GlaxoSmithKline generated $44.03B in revenue and $7.83B in net income.
GlaxoSmithKline's next earnings report is scheduled for July 28, 2026 before market open; analysts estimate EPS of $1.27.
GlaxoSmithKline quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $10.25B | +1.5% | $2.33B | $1.16 |
| Q4 2025 | $11.57B | +6.2% | $854.20M | $1.10 |
| Q3 2025 | $11.48B | +6.7% | $2.70B | $1.32 |
| Q2 2025 | $10.73B | +1.3% | $1.94B | $0.94 |
| Q1 2025 | $10.09B | +2.1% | $2.18B | $1.05 |
| Q4 2024 | $10.90B | +0.8% | $556.04M | $0.27 |
| Q3 2024 | $10.76B | -1.7% | $-77.90M | $-0.04 |
| Q2 2024 | $10.59B | +9.8% | $1.58B | $0.75 |
GlaxoSmithKline (GSK) — frequently asked questions
When does GlaxoSmithKline (GSK) report earnings next?
GlaxoSmithKline is expected to report earnings on July 28, 2026 before market open. Analysts estimate EPS of $1.27.
What was GSK's revenue last quarter?
GlaxoSmithKline reported revenue of $10.25B in Q1 2026, up 1.5% from the same quarter a year earlier.
What was GSK's EPS last quarter?
GlaxoSmithKline reported diluted EPS of $1.16 in Q1 2026.
Is GlaxoSmithKline profitable?
GlaxoSmithKline is currently profitable, with $7.83B in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)